Last reviewed · How we verify
SER-155
At a glance
| Generic name | SER-155 |
|---|---|
| Also known as | Cultivated Multi-Strain Live Bacterial Therapeutic, Encapsulated |
| Sponsor | Seres Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of SER-155 to Treat Diarrhea in People on Immunotherapy (PHASE1)
- A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SER-155 CI brief — competitive landscape report
- SER-155 updates RSS · CI watch RSS
- Seres Therapeutics, Inc. portfolio CI